First-line pyrotinib plus apatinib in advanced non-small cell lung cancer harboring HER2 mutations or amplification: a phase II trial.
Lung CancerAug 22, 2026 (epub)
Clinical ResearchOncology (Medical)
Yaning Yang, Wenxin Jiang, Guangjian Yang et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase II trial evaluated the efficacy of pyrotinib plus apatinib in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutations or amplification. The study found an overall response rate (ORR) of 72.7% and a median progression-free survival (PFS) of 10.7 months, indicating promising first-line activity.
Key findings
- The overall response rate (ORR) was 72.7% (95% CI, 49.8-89.3).
- The disease control rate (DCR) reached 95.5% (95% CI, 77.2-99.9).
- The median progression-free survival (PFS) was 10.7 months (95% CI, 6.6-14.8).
- Pyrotinib plus apatinib prolonged PFS compared to chemotherapy-based regimens (HR 0.53, P=0.003).
Why it matters
The study highlights a potential first-line treatment option for advanced HER2-altered NSCLC, which may offer rapid responses and manageable toxicity, particularly important in settings with limited access to traditional chemotherapy.